US Bancorp’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

US Bancorp’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,000	Closed	-$1K	–	3771
2016 Q2	$1K	Hold	2,000	–	–	﹤0.01%	3534
2016 Q1	$3K	Sell	2,000 -1,000	-33%	-$1.97K	﹤0.01%	3346
2015 Q4	$9K	Hold	3,000	–	–	﹤0.01%	3094
2015 Q3	$19K	Hold	3,000	–	–	﹤0.01%	2890
2015 Q2	$30K	Hold	3,000	–	–	﹤0.01%	2785
2015 Q1	$22K	Hold	3,000	–	–	﹤0.01%	2917
2014 Q4	$16K	Hold	3,000	–	–	﹤0.01%	2978
2014 Q3	$15K	Hold	3,000	–	–	﹤0.01%	2951
2014 Q2	$20K	Hold	3,000	–	–	﹤0.01%	2871
2014 Q1	$21K	Buy	+3,000	New	+$17.8K	﹤0.01%	2834

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

US Bancorp's NWBO Position: Q3 2016 in Review

US Bancorp sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2016, closing a stake of 2,000 shares — an estimated $1K sold.

US Bancorp first reported a position in NWBO in Q1 2014 and held it in 10 quarters. The position peaked at $30K in Q2 2015. 54 funds tracked by Wall St. Rank hold NWBO as of Q3 2016.

US Bancorp reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2016 after selling out during the quarter.
US Bancorp sold 2,000 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2016, an estimated $1K.
US Bancorp first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 10 quarters.
US Bancorp's Northwest Biotherapeutics, Inc. Common stock position peaked at $30K in Q2 2015.
54 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2016.

Based on US Bancorp's 13F filing for Q3 2016, filed 4 Nov 2016.